Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Toxicology and Applied Pharmacology

• Publication date

  1996-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0041-008X(96)80033-0PMID 8917700
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Snake F(ab′)2 Antivenom from Hyperimmunized Horse: Pharmacokinetics Following Intravenous and Intramuscular Administrations in Rabbits

  1995cited by this paper
• Response to specific Centruroides sculpturatus antivenom in 151 cases of scorpion stings.

  1994cited by this paper
• The treatment of the scorpion envenoming syndrome: the Saudi experience with serotherapy.

  1994cited by this paper
• Pharmacokinetics of Vipera aspis venom after experimental envenomation in rabbits.

  1994cited by this paper
• Scorpion envenomation and antivenom therapy.

  1994cited by this paper
• Antibody treatment of toxin poisoning--recent advances.

  1994cited by this paper
• The management of scorpion envenomation 1993.

  1993cited by this paper
• Experimental treatment protocols for scorpion envenomation: a review of common therapies and an effect of kallikrein-kinin inhibitors.

  1992cited by this paper
• Colchicine-specific Fab fragments alter colchicine disposition in rabbits.

  1992cited by this paper
• Issues in management of scorpion sting in children.

  1992cited by this paper
• Antivenin administration for Centruroides scorpion sting: risks and benefits.

  1991cited by this paper
• Redistribution of tricyclic antidepressants in rats using a drug-specific monoclonal antibody: dose-response relationship.

  1991cited by this paper
• The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects.

  1990cited by this paper
• Immunotoxicotherapy: present status and future trends.

  1989cited by this paper
• The influence of digoxin-specific antibody fragments on digoxin disposition in the rat.

  1987cited by this paper
• Redistribution into plasma of tracer doses of desipramine by anti-desipramine antiserum in rats.

  1987cited by this paper
• Neurotoxic Proteins in Scorpion Venom

  1984cited by this paper
• Pharmacokinetics of 125I-labelled antivenin to the venom from the scorpion Androctonus amoreuxi.

  1983cited by this paper
• Cardiovascular effects of venom from the scorpion Buthus occitanus, Amoreux.

  1980cited by this paper
• Calculation of average antibody affinity in anti-hapten sera from data obtained by competitive radioimmunoassay.

  1980cited by this paper
• Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

  1978cited by this paper
• Effects of sheep digoxin-specific antibodies and their Fab fragments on digoxin pharmacokinetics in dogs.

  1977cited by this paper
• Book reviewImmunoglobulins: Biological Aspects and Clinical Uses: EZIO MERLER, (ed.): National Academy of Sciences, Washington, D.C., 1971, 404 pp., $9.50.

  1971cited by this paper

• Pharmacokinetics of Snake Antivenom Following Intravenous and Intramuscular Administration in Envenomed Large Animal Model

  2025cites this paper
• Snake Antivenoms—Toward Better Understanding of the Administration Route

  2023cites this paper
• Neutralization of Centruroides tecomanus scorpion venom by the use of two human recombinant antibody fragments.

  2023cites this paper
• Developing a computational pharmacokinetic model of systemic snakebite envenomation and antivenom treatment.

  2022cites this paper
• The Pharmacological and Structural Basis of the AahII–NaV1.5 Interaction and Modulation by the Anti-AahII Nb10 Nanobody

  2022cites this paper
• Scorpion envenomation: a deadly illness requiring an effective therapy

  2020cites this paper
• Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits

  2020cites this paper
• A randomized comparative study between intravenous and intramuscular scorpion antivenom regimens in children

  2019cites this paper
• Improvement of purification methods for F(ab')2 fraction of equine hyperimmune plasma against scorpion venom

  2018cites this paper
• Pros and cons of different therapeutic antibody formats for recombinant antivenom development

  2018cites this paper
• Development of a new approach of immunotherapy against scorpion envenoming: Avian IgYs an alternative to equine IgGs

  2018cites this paper
• Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens

  2016cites this paper
• New Insights on the Pharmacokinetics of Venoms and Antivenoms

  2015cites this paper
• The Effect of a Polyvalent Antivenom on the Serum Venom Antigen Levels of Naja sputatrix (Javan Spitting Cobra) Venom in Experimentally Envenomed Rabbits

  2015cites this paper
• Pharmacokinetics of the Sri Lankan hump-nosed pit viper (Hypnale hypnale) venom following intravenous and intramuscular injections of the venom into rabbits.

  2014cites this paper
• Current Treatment for Venom-Induced Consumption Coagulopathy Resulting from Snakebite

  2014cites this paper
• Role of the animal model on the pharmacokinetics of equine-derived antivenoms.

  2013cites this paper
• Hemiscorpius lepturus envenomation: Manifestations and management with specific antivenom

  2013cites this paper
• The pharmacokinetics of Iranian scorpion Odonthubuthus doriae venom and the available antivenom

  2010cites this paper
• Neutralization of Bothrops asper venom by antibodies, natural products and synthetic drugs: contributions to understanding snakebite envenomings and their treatment.

  2009cites this paper
• Identification of potent nanobodies to neutralize the most poisonous polypeptide from scorpion venom.

  2009cites this paper
• Initial volume of a drug before it reaches the volume of distribution: pharmacokinetics of F(ab')2 antivenoms and other drugs.

  2007cites this paper
• Toxicokinetic and toxicodynamic analyses of Androctonus australis hector venom in rats: optimization of antivenom therapy.

  2007cites this paper
• Pharmacokinetics of whole IgG equine antivenom: comparison between normal and envenomed rabbits.

  2006cites this paper
• Using a recombinant bispecific antibody to block Na+-channel toxins protects against experimental scorpion envenoming

  2006cites this paper
• Anticorps recombinants : vers une nouvelle génération d'antivenins ?

  2006cites this paper
• Pharmacokinetics of a F(ab')2 scorpion antivenom in healthy human volunteers.

  2005cites this paper
• Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms.

  2005cites this paper
• Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapy.

  2005cites this paper
• Bacterial expression, purification and functional characterization of a recombinant chimeric Fab derived from murine mAb BCF2 that neutralizes the venom of the scorpion Centruroides noxius hoffmann.

  2004cites this paper
• Picaduras por alacranes y arañas ponzoñosas de México

  2004cites this paper
• Intramuscular administration of antivenoms in experimental envenomation by Bothrops asper: comparison between Fab and IgG.

  2003cites this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Immunoglobulin Therapy for Envenomation

  2003influential citation
• Intraspecific variability and pharmacokinetic characteristics of Androctonus mauretanicus mauretanicus scorpion venom.

  2002cites this paper
• Effects of antivenom on Buthus occitanus tunetanus (Bot) scorpion venom pharmacokinetics: towards an optimization of antivenom immunotherapy in a rabbit model.

  2001cites this paper
• [Biodynamics of the antigen-antibody reaction in vivo].

  2000cites this paper
• Scorpion envenomation and serotherapy in Morocco.

  2000cites this paper
• Mapping of an epitope recognized by a neutralizing monoclonal antibody specific to toxin Cn2 from the scorpion Centruroides noxius, using discontinuous synthetic peptides.

  1999cites this paper
• THE IMPROVEMENT AND STANDARDIZATION OF ANTIVENOM PRODUCTION IN DEVELOPING COUNTRIES: COMPARING ANTIVENOM QUALITY, THERAPEUTICAL EFFICIENCY, AND COST

  1999cites this paper
• Pharmacokinetics of the toxic fraction of Centruroides limpidus limpidus venom in experimentally envenomed rabbits and effects of immunotherapy with specific F(ab')2.

  1999cites this paper
• [Diagnosis and monitoring of hemorrhage due to viper envenomation in the African savanna].

  1999cites this paper
• Preclinical assessment of immunoreactivity of a new purified equine F(ab')2 against European viper venom.

  1998cites this paper
• Venoms, antivenoms and immunotherapy.

  1998cites this paper
• Interspecies scaling of clearance and volume of distribution for horse antivenom F(ab')2.

  1998cites this paper
• The Use of Antibodies As Therapeutic Agents in Toxicology

  1997cites this paper
• Immunotoxicotherapy: Successes, disappointments and hopes

  1997cites this paper